The usefulness of serum APM2 as a predictable marker for the response to platinum based antineoplastic drugs.

The usefulness of serum APM2 as a predictable marker for the response to platinum based antineoplastic drugs. - Serum APM2 as a predictable marker for platinum antineoplastic drug effects

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028487

Enrollment

100

Registered

2017-08-02

Start date

2012-12-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma, Gastric cancer, Esophageal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with malignant tumors and planned to be treated by chemotherapy. (2) Patients equal or over 20 years old.

Exclusion criteria

Exclusion criteria: Patients who are considered to be inappropriate candidate for this study by the investigator.

Design outcomes

Primary

Measure	Time frame
Serum APM2 concentration The effect of platinum antineoplastic drugs on the tumors.	—

Secondary

Measure	Time frame
Serum APM2 concentration The side-effects of platinum antineoplastic drugs on the tumors.	—

Countries

Japan

Contacts

Public ContactKenya Kamimura

same as above same as above

ethics@adm.niigata-u.ac.jp0252272207

Outcome results